Company intelligence / Profile preview
Healiva SA
Lugano, Switzerland
- Ownership
- Private
- Development stage
- Other
01
Overview
Developing personalized therapies combining cell therapies, enzyme technology, and medical devices for chronic and acute wounds; products in pre-clinical to market phase with focus on venous leg ulcers and diabetic foot ulcers.
- Therapeutic areas
- EndocrinologyCardiovascularDermatology
- Modalities
- Cell therapyEnzyme technologyMedical device
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
C4U Corporation (strategic alliance for CRISPR-Cas3 therapies for EB)Lausanne University Hospital (manufacturing EpiDex)Energenesis Biomedical (treatments for diabetic foot ulcers)
Beyond the preview
Go deeper on Healiva SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Healiva SA.